Iguratimod
- Generic Name
- Iguratimod
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C17H14N2O6S
- CAS Number
- 123663-49-0
- Unique Ingredient Identifier
- 4IHY34Y2NV
- Background
Iguratimod is under investigation in Rheumatoid Arthritis.
- Indication
用于活动性类风湿关节炎。
- Associated Conditions
- -
- Associated Therapies
- -
Iguratimod as Treatment for Refractory Lupus Nephritis
- First Posted Date
- 2017-02-15
- Last Posted Date
- 2017-02-27
- Lead Sponsor
- RenJi Hospital
- Target Recruit Count
- 30
- Registration Number
- NCT03054545
- Locations
- 🇨🇳
RenJi Hospital, Shanghai, Shanghai, China
Study of Iguratimod in Sjögren's Syndrome
- First Posted Date
- 2017-01-18
- Last Posted Date
- 2017-01-18
- Lead Sponsor
- Peking Union Medical College Hospital
- Target Recruit Count
- 30
- Registration Number
- NCT03023592
- Locations
- 🇨🇳
Peking Union Medical College Hospital, Beijing, Beijing, China
The Iguratimod Effect on Lupus Nephritis (IGeLU)
- Conditions
- Interventions
- First Posted Date
- 2016-10-18
- Last Posted Date
- 2018-12-19
- Lead Sponsor
- RenJi Hospital
- Target Recruit Count
- 120
- Registration Number
- NCT02936375
- Locations
- 🇨🇳
RenJi Hospital, Shanghai, Shanghai, China
🇨🇳Shanghai Tongji Hospital, Tongji University School of Medicine, Shanghai, Shanghai, China
Iguratimod in Kidney Transplant Recipients
- Conditions
- Interventions
- First Posted Date
- 2016-07-21
- Last Posted Date
- 2018-08-29
- Target Recruit Count
- 60
- Registration Number
- NCT02839941
- Locations
- 🇨🇳
The First Affiliated Hospital with Nanjing Medical University, Nanjing, Jiangsu, China
Study of Iguratimod Plus Methotrexate Compared to Leflunomid Plus Methotrexate in Patients With Rheumatoid Arthritis
- Conditions
- Interventions
- First Posted Date
- 2014-10-27
- Last Posted Date
- 2014-10-27
- Lead Sponsor
- Jiangsu Simcere Pharmaceutical Co., Ltd.
- Target Recruit Count
- 240
- Registration Number
- NCT02275299
- Locations
- 🇨🇳
Peking Union Medical College Hospital, Beijing, Beijing, China
Effectiveness of Iguratimod Versus Placebo to Treat Early Rheumatoid Arthritis on MRI
- First Posted Date
- 2013-07-08
- Last Posted Date
- 2014-10-23
- Lead Sponsor
- Jiangsu Simcere Pharmaceutical Co., Ltd.
- Target Recruit Count
- 200
- Registration Number
- NCT01893151
- Locations
- 🇨🇳
Third Affiliated Hospital Of Sun Yat-sen University, Guangzhou, Guangdong, China
Investigation of the Safety and Efficacy of Iguratimod in Patients With Rheumatoid Arthritis
- First Posted Date
- 2013-05-10
- Last Posted Date
- 2018-11-05
- Lead Sponsor
- Eisai Co., Ltd.
- Target Recruit Count
- 2747
- Registration Number
- NCT01850966
A Study of Iguratimod in Patients With Active Rheumatoid Arthritis
- First Posted Date
- 2012-03-15
- Last Posted Date
- 2020-10-14
- Lead Sponsor
- Jiangsu Simcere Pharmaceutical Co., Ltd.
- Target Recruit Count
- 1759
- Registration Number
- NCT01554917
- Locations
- 🇨🇳
Peking University People's Hospital, Beijing, China
Long-term Efficacy of Iguratimod Alone or Iguratimod in Combination With Methotrexate in Patients With Rheumatoid Arthritis
- First Posted Date
- 2012-03-08
- Last Posted Date
- 2016-02-23
- Lead Sponsor
- Jiangsu Simcere Pharmaceutical Co., Ltd.
- Target Recruit Count
- 910
- Registration Number
- NCT01548001
- Locations
- 🇨🇳
Renji Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.